Fig. 9From: Mithramycin delivery systems to develop effective therapies in sarcomasInhibition of SP1 signaling by free and nanocarrier delivered MTM. A Western blotting analyses of SP1 and several SP1 downstream targets in T-5 H-FC#1 cells treated with 0.1 µM free MTA or MTA-loaded nanoparticles for the indicated times. A control of a 48 h-treatment with empty NPs (Ce) for each formulation is included. B–C Western blotting analyses of SP1-related factors in T-5 H-FC#1 (B) and T-CDS-17#4 cells (C) treated with the indicated concentrations of the different MTM formulations for 48 h. β-Actin levels were used as loading controlsBack to article page